文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

以毛细血管再充盈时间为目标的个体化血流动力学复苏治疗早期脓毒性休克:ANDROMEDA-SHOCK-2随机临床试验

Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01
一句话结论早期脓毒性休克患者中,以毛细血管再充盈时间为目标的个体化血流动力学复苏方案在28天分层复合终点上优于常规治疗(胜率比1.16)。

该随机临床试验在19个国家86个中心纳入脓毒性休克起病4小时内的患者,比较以毛细血管再充盈时间为目标的个体化血流动力学复苏方案(CRT-PHR,n=720)与常规治疗(n=747)。CRT-PHR方案评估脉压、舒张压、容量反应性和床旁超声,据此调整液体、血管活性药和正性肌力药。主要终点为28天死亡、生命支持持续时间(血管活性药、机械通气、肾脏替代治疗)和住院天数的分层复合终点,CRT-PHR组胜率比为1.16(95%CI 1.02-1.33;P=0.04)。结论认为CRT-PHR优于常规治疗,主要归因于生命支持持续时间较短。

要点

  • 早期脓毒性休克起病4小时内启动以毛细血管再充盈时间为目标的个体化复苏,28天分层复合终点胜率比为1.16(95%CI 1.02-1.33;P=0.04)。
  • CRT-PHR组与常规治疗组在分层复合终点中的胜率分别为48.9%与42.1%,优势主要来自生命支持持续时间(26.4% vs 21.1%)。
  • 死亡单项胜率CRT-PHR组19.1% vs 常规治疗组17.8%,住院天数单项胜率3.4% vs 3.2%。
  • CRT-PHR方案在床旁评估脉压、舒张压、容量反应性和床旁超声,据此调整液体、血管活性药和正性肌力药。
  • 研究纳入86个中心、19个国家的1501例随机患者,主要分析纳入1467例,平均年龄66(17)岁,女性43.3%。

适用人群与场景

  • 脓毒性休克起病4小时内的患者,于2022年3月至2025年4月纳入,末次随访2025年7月。
  • 随机1501例,主要分析纳入1467例;平均年龄66(17)岁,女性43.3%。

处置流程与药物剂量

  • CRT-PHR方案包括评估脉压、舒张动脉压、容量反应性和床旁超声,据此调整液体、血管活性药和正性肌力药。
  • 对照组接受常规治疗。

研究设计与关键结果

  • 多中心随机临床试验,86个中心、19个国家,随机1501例,主要分析1467例;CRT-PHR组n=720,常规治疗组n=747。
  • 主要终点为28天死亡、生命支持持续时间(血管活性药、机械通气、肾脏替代治疗)和住院天数的分层复合终点,按入院时APACHE II评分中位数分层计算胜率比。
  • CRT-PHR组胜率131131次(48.9%)vs 常规治疗组112787次(42.1%),胜率比1.16(95%CI 1.02-1.33;P=0.04)。
  • 死亡单项胜率CRT-PHR组19.1% vs 常规治疗组17.8%;生命支持持续时间单项胜率26.4% vs 21.1%;住院天数单项胜率3.4% vs 3.2%。
  • 结论认为CRT-PHR优于常规治疗,主要归因于生命支持持续时间较短。

证据类型、等级与局限

  • 证据类型:随机临床试验(RCT)。
  • 试验注册号:ClinicalTrials.gov NCT05057611。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在早期脓毒性休克起病4小时内的患者中,采用以毛细血管再充盈时间为目标的个体化血流动力学复苏方案(评估脉压、舒张压、容量反应性和床旁超声,据此调整液体、血管活性药和正性肌力药)较常规治疗改善了28天分层复合终点,主要因生命支持持续时间缩短。
  • CRT-PHR组与常规治疗组死亡单项胜率分别为19.1%与17.8%,住院天数单项胜率分别为3.4%与3.2%。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The optimal strategy for hemodynamic resuscitation in early septic shock remains uncertain.

OBJECTIVE: To determine the effect of a personalized hemodynamic resuscitation protocol targeting capillary refill time (CRT-PHR) on a hierarchical composite outcome of mortality, duration of vital support, and length of hospital stay.

DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted in 86 centers in 19 countries. Patients within the first 4 hours of septic shock were included between March 2022 and April 2025, with last follow-up in July 2025.

INTERVENTIONS: Patients were randomized to undergo CRT-PHR (n = 720), including assessment of pulse pressure, diastolic arterial pressure, fluid responsiveness, and bedside echocardiography, to tailor fluids, vasopressors, and inotropes, vs usual care (n = 747).

MAIN OUTCOMES AND MEASURES: The primary outcome was a hierarchical composite of mortality, duration of vital support (vasoactives, mechanical ventilation, and kidney replacement therapy), and length of hospital stay assessed at 28 days. A win ratio was calculated for the primary outcome by comparing all possible patient pairs, starting with the first event in the hierarchy and stratified by median APACHE (Acute Physiology and Chronic Health Evaluation) II score at admission. Secondary outcomes were mortality, vital support-free days, and length of hospital stay at 28 days.

RESULTS: From 1501 randomized patients, 1467 were included in the primary analysis (mean age, 66 [17] years; 43.3% female). There were 131 131 wins (48.9%) in the CRT-PHR group vs 112 787 (42.1%) in the usual care group for the hierarchical composite primary outcome, with a win ratio of 1.16 (95% CI, 1.02-1.33; P = .04). Individual wins for death were 19.1% vs 17.8%; duration of vital support, 26.4% vs 21.1%; and length of hospital stay, 3.4% vs 3.2% in the intervention vs usual care groups, respectively.

CONCLUSIONS AND RELEVANCE: Among patients with early septic shock, a personalized hemodynamic resuscitation protocol targeting capillary refill time was superior to usual care for the primary composite outcome, primarily due to a lower duration of vital support.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05057611.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Hernandez G, Ospina-Tascón GA, Kattan E, et al. Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial. JAMA. 2025. PMID: 41159835. doi:10.1001/jama.2025.20402

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。